(MENAFN- GlobeNewsWire - Nasdaq) CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in November:

• Guggenheim's 2^nd Annual Healthcare Innovation Conference on Monday, November 10, 2025 at 11:00-11:25 a.m. ET
• Jefferies 2025 Global Healthcare Conference on Wednesday, November 19, 2025 at 11:30-11:55 a.m. ET (4:30-4:55 p.m. GMT)
  

The fireside chats will be webcast live and may be accessed through Relay Therapeutics' website under Events in the News & Events section through the following link: . An archived replay of the webcast will be available for up to 30 days following the event.

About Relay Therapeutics

Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. Relay's Dynamo^® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The company's lead clinical asset, RLY-2608, is the first pan-mutant selective PI3Kα inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. RLY-2608 is also being investigated in a group of genetic disease indications called PI3Kα-driven vascular malformations. Relay's pipeline also includes late-stage research programs for NRAS-driven solid tumors and Fabry disease. For more information, please visit or follow us on LinkedIn.

Contact:
Pete Rahmer
...

Media:
Dan Budwick
1AB
973-271-6085
dan@1abmedia

MENAFN03112025004107003653ID1110289275